13th edition

Format
HYBRID

December 3rd & 4th, 2024

IN-PERSON | LILLE, FR

December 11th& 12th 2024

ONLINE MEETINGS

Agnostic or pure players in the biotech sector: Who is becoming prominent in the early-stage financing rounds?

Agnostic or pure players in the biotech sector: Who is becoming prominent in the early-stage financing rounds?

The seed investment market is comprised of players with varied degrees of specialisation, from totally agnostic players involved in multiple industries, to pure players focusing on specific therapeutic areas. Do most specialised funds attract the more generalist types in the financing rounds? What is the importance of the amount of seed investment today for cross-industry funds, 100% healthcare-oriented funds, and pure players in the biotech industry, respectively?

Joseph Wagman

Junior Analyst
United Kingdom
SOSV

Jacky Vonderscher

CEO
France
ENYO Pharma

Jeroen Bakker

Senior Associate
The Netherlands
Novo Seeds

Jean-Charles Brosse

Partner Healthcare and Life Sciences
France
Positive Capital

Jan Adams

Managing Director
Germany
EMBL Ventures

Jonathan Tobin

Investment Director
United Kingdom
Arix Bioscience
Scroll to Top
  • No products in the cart.